Ocrelizumab Superior for Delaying Disability Progression in Primary Progressive MS

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on June 1, 2026.

via HealthDay

MONDAY, June 1, 2026 -- For patients with primary progressive multiple sclerosis (PPMS), ocrelizumab is superior for delaying disability progression, according to a study published in the May 30 issue of The Lancet.

Gavin Giovannoni, M.D., from the Royal London Hospital, and colleagues examined the effect of ocrelizumab in older and more disabled patients with PPMS, particularly regarding hand function preservation, in a multicenter, randomized, placebo-controlled phase 3b study conducted at 138 sites in 22 countries. Patients with PPMS aged 18 to 65 years with an Expanded Disability Status Scale score of 3.0 to 8.0 were randomly assigned to intravenous ocrelizumab 600 mg or placebo every six months for 144 weeks (505 and 508 patients, respectively).

The researchers found that the proportion of patients with 12-week composite confirmed disability progression was 33 and 40 percent, respectively, with ocrelizumab and placebo (hazard ratio, 0.70; relative risk reduction, 30 percent). A similar, significant risk reduction was seen in the subset of patients with magnetic resonance imaging activity at baseline (risk reduction, 55 percent). Both groups had a similar overall safety profile. More infections were seen with ocrelizumab (48 versus 45 percent), but the difference was attenuated after exclusion of COVID-19 (38 versus 37 percent). The groups had similar rates of serious adverse events and serious infections.

"These findings are important because they show that treatment can make a meaningful difference to people with more advanced forms of MS and can help preserve hand and arm function, which is important for maintaining independence, daily activities, and quality of life," Giovannoni said in a statement.

Several authors disclosed ties to biopharmaceutical companies, including F. Hoffmann La Roche, which manufactures ocrelizumab and funded the study.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-06-02 00:30

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords